Claims for Patent: 7,514,594

Summary for Patent: 7,514,594

Title:	Transgenic animal model of bone mass modulation
Abstract:	The present invention relates to methods and materials used to express the HBM protein in animal cells and transgenic animals. The present invention also relates to transgenic animals expressing the high bone mass gene, the corresponding wild-type gene, and mutants thereof. The invention provides nucleic acids, including coding sequences, oligonucleotide primers and probes, proteins, cloning vectors, expression vectors, transformed hosts, methods of developing pharmaceutical compositions, methods of identifying molecules involved in bone development, and methods of diagnosing and treating diseases involved in bone development. In preferred embodiments, the present invention is directed to methods for treating, diagnosing and preventing osteoporosis.
Inventor(s):	Askew; G. Roger (Boxford, MA), Babij; Philip (Dunstable, MA), Bex, III; Frederick James (Newton Square, PA), Van Nest Bodine; Peter (Havertown, PA)
Assignee:	Wyeth (Madison, NJ)
Application Number:	10/680,287
Patent Claims:	1. A transgenic mouse having somatic and germ cells comprising a stably integrated nucleic acid which comprises a murine or viral promoter region that directs protein expression in transgenic mouse bone cells that is operably linked to a sequence encoding a human HBM protein or a sequence encoding a mouse LRP5 protein having a glycine 170 to valine substitution, and wherein said transgenic mouse has increased bone density. 2. A transgenic mouse having somatic and germ cells comprising a stably integrated nucleic acid which comprises SEQ ID NO: 2 or a mouse nucleic acid encoding an LRP having a glycine 170 to valine substitution, and wherein the nucleic acid further comprises an operably linked murine or viral promoter region that directs protein expression in mouse bone cells, and wherein bone mass is increased relative to non-transgenic mice in more than one parameter selected from among bone density, bone strength, trabecular number, bone size, and bone tissue connectivity. 3. The transgenic mouse of claim 1, wherein the nucleic acid comprises SEQ ID NO: 2. 4. A transgenic mouse for the study of bone density modulation having somatic and germ cells comprising a stably integrated nucleic acid which comprises a murine or viral promoter region that directs protein expression in mouse bone cells, wherein the promoter region is operably linked to a sequence encoding SEQ ID NO: 4 or a sequence encoding a mouse LRP5 protein having a glycine 170 to valine substitution, wherein bone mass is increased relative to non-transgenic mice in more than one parameter selected from among bone density, bone strength, trabecular number, bone size, and bone tissue connectivity. 5. The transgenic mouse of claim 1, wherein the promoter region is a bone specific promoter region. 6. The transgenic mouse of claim 4, wherein the promoter region is a bone specific promoter region. 7. The transgenic mouse of claim 1, wherein the promoter region is a CMV.beta.Actin promoter region. 8. The transgenic mouse of claim 1, wherein the promoter region is a type I collagen promoter region. 9. The transgenic mouse of claim 1, wherein the transgenic mouse expresses SEQ ID NO: 4. 10. The transgenic mouse of claim 1, wherein bone mass is increased relative to a wild-type mouse in more than one parameter selected from among bone density, bone strength, trabecular number, bone size, and bone tissue connectivity. 11. The transgenic mouse of claim 1, wherein a human HBM protein is expressed, and wherein the transgenic mouse is fertile and passes to its offspring the nucleic acid encoding SEQ ID NO: 4. 12. The transgenic mouse of claim 4, wherein SEQ ID NO: 4 is expressed, and wherein the transgenic mouse is fertile and passes to its offspring the nucleic acid encoding SEQ ID NO: 4. 13. The transgenic mouse of claim 1, wherein the murine or viral promoter region is selected from the group consisting of CMV, RSV, SV40, EF-1a, histone, TGF.beta.1, MSX2, c-fos/c-jun, Cbfa1, Fra/Jun, D1x5, osteocalcin, osteopontin, bone sialoprotein, collagenase, alkaline phosphatase, and MGP. 14. A transgenic mouse having somatic and germ cells comprising a stably integrated nucleic acid which comprises a viral or murine bone-specific promoter region that directs protein expression in mouse bone cells that is operably linked to a sequence encoding SEQ ID NO: 4 or a sequence encoding a mouse LRP5 protein having a glycine 170 to valine substitution, and wherein bone mass is increased relative to non-transgenic mice in more than one parameter selected from among bone density, bone strength, trabecular number, bone size, and bone tissue connectivity. 15. The transgenic mouse of claim 1, wherein the sequence comprises SEQ ID NO: 2; the murine or viral promoter region is selected from the group consisting of CMV, RSV, SV40, EF-1a, histone, TGFBB1, MSX2, c-fos/c-jun, Cbfa1, Fra/Jun, D1x5, osteocalcin, osteopontin, bone sialoprotein, collagenase, alkaline phosphatase, and MGP, and wherein the transgenic mouse has increased bone density as compared to non-transgenic mice.

Details for Patent 7,514,594

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2039-03-29